Who are sequential versus triple's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexilant, Nexium, Protonix, Protonix, Pantoprazole Sodium, Aciphex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sequential-versus-triple.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

sequential versus triple — Competitive Intelligence Brief

sequential versus triple (sequential versus triple) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor. Area: Gastroenterology.

marketed Proton pump inhibitor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

sequential versus triple (sequential versus triple) — Jun-Won Chung. Sequential versus triple therapy is used to treat Helicobacter pylori infections by combining antibiotics to eradicate the bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sequential versus triple TARGET	sequential versus triple	Jun-Won Chung	marketed	Proton pump inhibitor
Dexilant	DEXLANSOPRAZOLE	Takeda	marketed	Proton Pump Inhibitor [EPC]	(H+, K+)-ATPase	2009-01-01
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Protonix	Pantoprazole Sodium	Baxter	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme system	2000-01-01
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01
Aciphex	rabeprazole	Waylis	marketed	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-07 — Pantoprazole Sodium · 7544370 · US
2026-12-07 — Pantoprazole Sodium · 7544370*PED · US

Sponsor landscape (Proton pump inhibitor class)

Samsung Medical Center · 2 drugs in this class
Bayer · 1 drug in this class
GBG Forschungs GmbH · 1 drug in this class
HK inno.N Corporation · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
Jason Lang, M.D., M.P.H. · 1 drug in this class
Jun-Won Chung · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Shandong New Time Pharmaceutical Co., LTD · 1 drug in this class
AVM Biotechnology Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sequential versus triple — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-versus-triple. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab